Cefprozil (cefprozil)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Cefprozil is a semisynthetic, second generation cephalosporin antibiotic.
Cefprozil is used orally for the treatment of mild to moderate respiratory tract infections (i.e., acute sinusitis, secondary bacterial infections of acute bronchitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia+) caused by susceptible bacteria. The drug also is used orally for the treatment of acute otitis media caused by susceptible bacteria, pharyngitis and tonsillitis caused by Streptococcus pyogenes (group A beta-hemolytic streptococci), and mild to moderate uncomplicated skin and skin structure infections caused by susceptible bacteria.
Generic name: cefprozil
Pronunciation: (seff-PRO-zill)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Cefprozil
Indications
The following indications are listed for Cefprozil:
- Acute Haemophilus Influenzae Bacterial Sinusitis
- Acute Moraxella Catarrhalis Bacterial Sinusitis
- Acute Streptococcus Pneumoniae Bacterial Sinusitis
- Haemophilus Influenzae Acute Otitis Media
- Haemophilus Influenzae Bronchitis
- Moraxella Catarrhalis Acute Otitis Media
- Moraxella Catarrhalis Bronchitis
- Pharyngitis Due To Streptococcus Pyogenes
- Pneumococcal Acute Otitis Media
- Skin And Skin Structure Streptococcus Pyogenes Infection
- Staphylococcus Aureus Skin And Skin Structure Infection
- Streptococcus Pneumoniae Bronchitis
- Tonsillitis Due To Streptococcus Pyogenes
Also known as: Acute Otitis Media Due To Diplococcus Pneumoniae, Acute Otitis Media Due To Fraenkel's Pneumococcus, Acute Otitis Media Due To H. Flu, Acute Otitis Media Due To Haemophilus Influenzae, Acute Otitis Media Due To Hemophilus Influenzae, Acute Otitis Media Due To Influenza Bacillus, Acute Otitis Media Due To Moraxella Catarrhalis, Acute Otitis Media Due To Pfeiffer's Bacillus, Acute Otitis Media Due To Pneumococcus, Acute Otitis Media Due To Pneumonococcus, Acute Otitis Media Due To Streptococcus Pneumoniae, Acute Sinusitis Due To B. Catarrhalis, Acute Sinusitis Due To Branhamella Catarrhalis, Acute Sinusitis Due To Diplococcus Pneumoniae, Acute Sinusitis Due To Fraenkel's Pneumococcus, Acute Sinusitis Due To Fraenkel's Pneumonococcus, Acute Sinusitis Due To H. Flu, Acute Sinusitis Due To H. Influenzae, Acute Sinusitis Due To Haemophilus Influenzae, Acute Sinusitis Due To Hemophilus Influenzae, Acute Sinusitis Due To Influenza Bacillus, Acute Sinusitis Due To M. Catarrhalis, Acute Sinusitis Due To Moraxella Catarrhalis, Acute Sinusitis Due To Neisseria Catarrhalis, Acute Sinusitis Due To Pfeiffer's Bacillus, Acute Sinusitis Due To Pneumococcus, Acute Sinusitis Due To Streptococcus Pneumoniae, Acute Sinusitis From Fraenkel-Weichselbaum Pneumococcus, Bronchitis Due To B. Catarrhalis, Bronchitis Due To Branhamella Catarrhalis, Bronchitis Due To Diplococcus Pneumoniae, Bronchitis Due To Fraenkel's Pneumococcus, Bronchitis Due To Fraenkel-Weichselbaum Pneumococcus, Bronchitis Due To H. Flu, Bronchitis Due To H. Influenzae, Bronchitis Due To Haemophilus Influenzae, Bronchitis Due To Hemophilus Influenzae, Bronchitis Due To Influenzae Bacillus, Bronchitis Due To M. Catarrhalis, Bronchitis Due To Moraxella Catarrhalis, Bronchitis Due To Neisseria Catarrhalis, Bronchitis Due To Pfeiffer's Bacillus, Bronchitis Due To Pneumococcus, Bronchitis Due To Pneumonococcus, Bronchitis Due To Streptococcus Pneumoniae, Epidemic Sore Throat, Fraenkel-Weichselbaum Pneumococcus Acute Otitis Media, Pharyngitis Due To Group A Beta-Hemolytic Streptococci, Pharyngitis Due To Streptococcus Epidemicus, Septic Sore Throat, Skin & Skin Soft Tissue Streptococcus Pyogenes Infection, Skin And Skin Soft Tissue Staphylococcus Aureus Infection, Streptococcal Pharyngitis, Streptococcus Pyogenes Tonsillitis.
Dosing
Cefprozil is commercially available as the monohydrate; dosage is expressed in terms of anhydrous cefprozil.
In patients with creatinine clearances less than 30 mL/minute, dose but not frequency of administration of cefprozil should be modified; such patients should receive 50% of the usual cefprozil dose using the usual dosing period. Because the drug is partially removed by hemodialysis, cefprozil should be administered to patients undergoing hemodialysis after the end of the dialysis period.
Modification of usual dosage of cefprozil is not necessary in patients with hepatic impairment.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Reproduction studies in mice, rats, or rabbits using oral cefprozil in dosages 0.8, 8.5, or 18.5 times, respectively, the maximum daily human dose (1 g) based upon mg/m2 have not revealed evidence of harm to the fetus. There are no adequate and well-controlled studies to date using cefprozil in pregnant women or during labor and delivery, and the drug should be used during pregnancy or labor and delivery only when clearly needed.
Because trace concentrations of cefprozil (less than 0.3% of a dose) are distributed into milk, the drug should be used with caution in nursing women.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.